- Home
- / BenevolentAI
BenevolentAI
Market Valuation
$1 B
2017-05-02
Total Funding
$305 M
Revenue
€7.3 M
FY, 2023
BenevolentAI Summary
Company Summary
- Overview
- BenevolentAI is a clinical-stage AI-enabled drug discovery company. It offers a Benevolent Platform that features clinical sub-typing, biomarker assessment, experimental hypothesis validation, indication expansion and drug repurposing, etc.
- Type
- Private
- Status
- Active
- Founded
- 2013
- HQ
- London, GB | view all locations
- Website
- https://www.benevolent.com/
- Cybersecurity rating
Table of Contents
Key People
Susan Liautaud, Non-Executive Director
Ivan Griffin, COO and Co-Founder
Nigel Shadbolt, Non-Executive Director
Operating MetricsView all
Trademarks Pending
2
May, 2020
LocationsView all
2 locations detected
London, England HQ
United Kingdom
4-8 Maple St, Bloomsbury
Babraham, England
United Kingdom
Babraham Hall House
BenevolentAI Financials
Summary Financials
- Revenue (H1, 2024)
- €2.8M
- Gross profit (H1, 2024)
- €935.0K
- Net income (H1, 2024)
- (€24.8M)
- Cash (H1, 2024)
- €23.0M
- EBIT (H1, 2024)
- (€32.3M)
- Enterprise value
- $977.0M